Idvynso is a complete HIV treatment regimen in a once-a-day tablet. Combining the long-studied doravirine with islatravir, a newer NRTI, it attacks the virus in multiple ways. Idvynso is made by Merck and was FDA-approved in April 2026. Idvynso is the first tenofovir-free, non-integrase-inhibitor, once-daily two-drug tablet shown to work as well as Biktarvy in clinical trials. Idvynso does not cure HIV and is meant to replace an existing viral suppression regimen.
Idvynso may be prescribed for the treatment of HIV in:
Idvynso is not for people taking a strong CYP3A enzyme inducer, or lamivudine or emtricitabine.
Doravirine, the NNRTI in Idvynso, blocks reverse transcriptase, the enzyme HIV uses to convert its genetic material into a form your cells can copy. Without that step, the virus can’t make new copies of itself.
Islatravir is a newer NRTI that works differently from older ones. Instead of simply stopping the copying process, it jams reverse transcriptase so the enzyme can’t move along the viral genetic material, and it also disrupts the copy itself. This dual action is something older NRTIs don’t have.
Idvynso (100 mg of doravirine and 0.25 mg of islatravir) is to be taken once a day in one tablet, with or without food.
If you take rifabutin alongside Idvynso, your provider will want you to take a separate 100 mg tablet of doravirine about 12 hours after your Idvynso dose as part of your rifabutin regimen. Never take two doses of Idvynso at once.
Idvynso’s FDA approval was built on the results of two phase 3 active-controlled, non-inferiority clinical trials in adults whose virus was already suppressed. Across both trials, 708 people received Idvynso, and 38 percent identified as Black or African American.
Trial 052 was a double-blind study of 342 people who switched from Biktarvy to Idvynso and 171 people remained on Biktarvy. At 48 weeks, both sets maintained undetectable status at 92 and 94 percent, respectively, showing that the two regimens worked nearly equally well.
Trial 051 was an open-label study of 366 people who switched to Idvynso from a variety of regimens, and 185 people remained on their existing regimens. At 48 weeks, both sets maintained undetectable status at 96 and 92 percent, respectively. The results were consistent across age, sex, and race in both trials.
Weight change was mixed across both trials. Those in Trial 052 saw essentially no change in weight (-0.03 kg) when switching to Idvynso and gained some weight on Biktarvy (+0.28 kg). However, in Trial 051, those who switched to Idvynso saw some weight gain (+0.94 kg) compared to those who stayed on their existing regimen (-0.15 kg). It is important to note that several of the people who switched to Idvynso were previously on regimens containing efavirenz or tenofovir disoproxil fumarate, which are both associated with weight loss.
Possible side effects include:
Discontinue Idvynso immediately and seek medical treatment right away for:
It is worth noting that Idvynso does not treat hepatitis B. If you have both HIV and hepatitis B, switching to Idvynso from a regimen that was also controlling your hepatitis B means you will likely need a separate medication for it. Tell your doctor if you have or have ever had hepatitis B.
The importance of staying on schedule
Do not miss or skip doses of Idvynso. This raises your risk of building resistance to the medication. Take it at the same time every day and avoid running out of it.
Idvynso is not to be combined with a strong CYP3A enzyme inducer, or lamivudine or emtricitabine. If you have taken rifabutin in the past four weeks before starting Idvynso, tell your doctor. Always tell your doctor about every medication and supplement you take so they can check for these interactions before you start Idvynso.
Tell your healthcare provider if you have:
Black people tend to be hit the hardest with HIV, making up 39 percent of new HIV diagnoses in 2024, despite being only 12 percent of the U.S. population. Black people with HIV are also among the least likely of any race to receive medical care within a month of diagnosis. Gaps in treatment can stem from insurance coverage, transportation, housing instability, provider bias, and medical mistrust.
Idvynso is still a new HIV regimen, only approved in April 2026, so it hasn’t built up the same amount of data that other HIV regimens may have, especially for Black patients. However, the trials that have been performed for Idvynso have had higher representation of Black patients compared to many HIV trials of the past. Black or African American patients made up between 31 and 45 percent of the two trials’ populations and treatment results were consistent across race, sex, and age groups.
If you’re worried about weight gain on an HIV regimen, Idvynso is not an integrase inhibitor (INSTI), nor does it contain tenofovir alafenamide, which tends to be associated with higher weight gain in Black patients and women. If you’ve experienced weight gain on INSTI-based regimens like dolutegravir or bictegravir, Idvynso could be a better option. Don’t be afraid to ask your provider about your options if weight gain is a concern.
Merck offers copay assistance through the Merck Access Program that may bring your out-of-pocket cost for Idvynso to as low as $0 per prescription if you have commercial insurance. Call 1-877-709-4455 or visit merckaccessprogram-IDVYNSO.com for more information about eligibility.
Merck also works with the ADAP Crisis Task Force to help provide Idvynso to eligible populations. Every state has an AIDS Drug Assistance Program (ADAP) that helps cover HIV medication costs for those who are uninsured or underinsured and meet certain income limits.
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking any drug or commencing or discontinuing any course of treatment.
There isn't enough information yet to know how Idvynso affects pregnancy, so it usually isn't the first choice if you're pregnant or trying to become pregnant. There is not enough human data available, not because Idvynso is unsafe. Always tell your doctor if you become pregnant or plan to become pregnant while on Idvynso.
There is no evidence that Idvynso affects fertility in male or female patients with HIV.
Current U.S. guidelines now support breastfeeding in those with sustained undetectable viral load on effective treatment. However, there is not enough data on whether Idvynso can pass into breastmilk or affect a breastfed infant. Always ask your doctor before you consider breastfeeding on Idvynso.
If you miss a dose of Idvynso, always take it as soon as you remember to. If it is almost time for you to take your next dose of Idvynso, skip the one you missed and take the next one as scheduled. Do not double up on your dose. If you consistently miss doses, tell your doctor.
Depending on which regimen you switch from, you may gain or lose weight with Idvynso. Weight change was mixed across two clinical trials for Idvynso. Those in Trial 052 lost small amounts of weight (about -0.03 kg) switching to Idvynso and gained some weight on Biktarvy® (+0.28 kg). However, in Trial 051, those who switched to Idvynso saw some weight gain (+0.94 kg) compared to those who stayed on their existing regimen (-0.15 kg). To note, several of the people who switched to Idvynso were previously on regimens containing efavirenz or tenofovir disoproxil fumarate, which are both associated with weight loss.
If your viral load is undetectable while on Idvynso, you cannot transmit HIV through sex. Undetectable = Untransmittable, or U=U, applies. U=U does not apply to sharing needles or breastfeeding.